Kate Lathrop

482 total citations
25 papers, 284 citations indexed

About

Kate Lathrop is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kate Lathrop has authored 25 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 9 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kate Lathrop's work include HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (6 papers) and Advanced Breast Cancer Therapies (5 papers). Kate Lathrop is often cited by papers focused on HER2/EGFR in Cancer Research (9 papers), Cancer Treatment and Pharmacology (6 papers) and Advanced Breast Cancer Therapies (5 papers). Kate Lathrop collaborates with scholars based in United States, China and Switzerland. Kate Lathrop's co-authors include Virginia Kaklamani, Robin J. Leach, Pankil Shah, Jing Wang, Pierre-Yves Dietrich, Ruben A. Mesa, Nicolas Mach, Dimpy P. Shah, Mariagrazia Di Marco and Sana Intidhar Labidi‐Galy and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Kate Lathrop

24 papers receiving 283 citations

Peers

Countries citing papers authored by Kate Lathrop

Since Specialization

Citations

This map shows the geographic impact of Kate Lathrop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kate Lathrop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kate Lathrop more than expected).

Fields of papers citing papers by Kate Lathrop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kate Lathrop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kate Lathrop. The network helps show where Kate Lathrop may publish in the future.

Co-authorship network of co-authors of Kate Lathrop

This figure shows the co-authorship network connecting the top 25 collaborators of Kate Lathrop. A scholar is included among the top collaborators of Kate Lathrop based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kate Lathrop. Kate Lathrop is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial 2024 ·Nature Communications ·(unknown), William Kelly, Virginia Kaklamani, Kate Lathrop, (unknown), (unknown), Gangadhara R. Sareddy, Joel Michalek, Andrea Gilbert, (unknown), Stefano Tiziani, Renu Pandey, (unknown), Alessia Lodi, John Floyd, Andrew Brenner	12
2	Abstract B117: HT Helper Study: A phone application + patient navigation to improve medication adherence among Latina breast cancer patients experiencing social determinants of health 2024 ·Cancer Epidemiology Biomarkers & Prevention ·Patricia Chalela, (unknown), (unknown), (unknown), (unknown), (unknown), Byeong Yeob Choi, Edgar Muñoz, (unknown), (unknown), (unknown), Asra Aslam, (unknown), (unknown), Virginia Kaklamani, Kate Lathrop, (unknown), (unknown), David Akopian, Amelie G. Ramírez	1
3	Genomic and transcriptomic landscape of HER2-low breast cancer 2024 ·Breast Cancer Research and Treatment ·(unknown), Tolulope Adeyelu, Andrew Elliott, Phillip L. Walker, Matías A. Bustos, Estelamari Rodríguez, Melissa Accordino, Jane Meisel, Margaret E. Gatti‐Mays, Emily Hsu, Kate Lathrop, Virginia Kaklamani, Matthew J. Oberley, George W. Sledge, Sarah Sammons, Stephanie L. Graff	4
4	Poziotinib treatment in patients with HER2-positive advanced breast cancer who have received prior anti-HER2 regimens 2024 ·Breast Cancer Research and Treatment ·Azadeh Nasrazadani, Juan Luis Gomez Marti, Kate Lathrop, Alvaro Restrepo, Szu-Yun Leu, Gajanan Bhat, Adam Brufsky	1
5	CTNI-10. SACITUZUMAB GOVITECAN FOR BREAST CANCER BRAIN METASTASIS 2023 ·Neuro-Oncology ·(unknown), William Kelly, (unknown), Andrea Gilbert, Joel Michalek, Virginia Kaklamani, Kate Lathrop, (unknown), John Floyd, Andrew Brenner	1
6	215P Impact of HER2 low on survival in patients treated with standard therapies in advanced breast cancer 2023 ·ESMO Open ·Stephanie L. Graff, (unknown), (unknown), Andrew Elliott, (unknown), Estelamari Rodríguez, Melissa Accordino, Jane Meisel, Margaret E. Gatti‐Mays, Emily Hsu, Kate Lathrop, Virginia Kaklamani, Matthew J. Oberley, G. W. Sledge, Sarah Sammons	3
7	Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer 2023 ·Cancer Research ·(unknown), (unknown), (unknown), Matías A. Bustos, Estelamari Rodríguez, Sarah Sammons, Melissa Accordino, Jane Meisel, Margaret E. Gatti‐Mays, Emily Hsu, Kate Lathrop, Virginia Kaklamani, Matthew J. Oberley, W. Michael Korn, Stephanie L. Graff	2
8	mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers 2023 ·Breast Cancer Research ·Hakim Bouamar, (unknown), Kate Lathrop, Ismail Jatoi, Andrew Brenner, Alia Nazarullah, (unknown), Michael Garcia, Yidong Chen, Virginia Kaklamani, Lu‐Zhe Sun	5
9	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer 2021 ·Cancer Cell ·Alfredo Addeo, Pankil Shah, Natacha Bordry, (unknown), (unknown), Mariagrazia Di Marco, Virginia Kaklamani, Pierre-Yves Dietrich, Barbara S. Taylor, (unknown), Darpan I. Patel, Jing Wang, Sana Intidhar Labidi‐Galy, (unknown), Robin J. Leach, José Luís Sandoval, Ruben A. Mesa, Kate Lathrop, Nicolas Mach, Dimpy P. Shah	137
10	Abstract PD13-05: Delivery and activity of SN-38 by sacituzumab govitecan in breast cancer brain metastases 2021 ·Cancer Research ·Andrew Brenner, Renu Pandey, (unknown), John Floyd, (unknown), Virginia Kaklamani, Kate Lathrop, (unknown), Stefano Tiziani	14
11	Abstract PS11-26: A phase 1 study of D-0502, an orally bioavailable SERD, for advanced or metastatic HR-positive and HER2-negative breast cancer 2021 ·Cancer Research ·Cynthia Osborne, Donald Richards, Sharon Wilks, Sami Diab, Dejan Juric, Kate Lathrop, Andrea Silber, William J. Edenfield, (unknown), (unknown), Binghe Xu, Tao Sun, Quchang Ouyang, Yanxia Shi, (unknown), Zhe Shi, Ling Zhang, Yaolin Wang, Erika Hamilton	18
12	Abstract PS5-31: Molecular markers of response to s-equol, a novel oral estrogen receptor (ER) beta agonist for triple negative breast cancer 2021 ·Cancer Research ·Kate Lathrop, Virginia Kaklamani, Andrew Brenner, Rong Li, Alia Nazarullah, (unknown), (unknown), Jonathan Gelfond, (unknown), Richard Elledge	2
13	Abstract PD1-07: A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy 2021 ·Cancer Research ·Adam Brufsky, (unknown), Julio A. Peguero, Kate Lathrop, Gajanan Bhat, François Lebel	5
14	373MO Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours 2020 ·Annals of Oncology ·Andrew Brenner, Renu Pandey, (unknown), (unknown), (unknown), (unknown), Virginia Kaklamani, Kate Lathrop, (unknown), Jean Caron, Stefano Tiziani	11
15	ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer 2020 ·BMC Medical Genomics ·(unknown), Xi Tan, (unknown), (unknown), (unknown), Chih‐Wei Chou, (unknown), (unknown), Nameer B. Kirma, Chun‐Liang Chen, Ching‐Hung Lin, Kate Lathrop, Richard Elledge, Virginia Kaklamani, Kohzoh Mitsuya, Tim H.‐M. Huang	9
16	CTNI-07. DELIVERY AND ACTIVITY OF SN-38 BY SACITUZUMAB GOVITECAN IN CNS TUMORS 2020 ·Neuro-Oncology ·Andrew Brenner, John Floyd, Renu Pandey, (unknown), (unknown), Virginia Kaklamani, Kate Lathrop, (unknown), Jean Caron, Stefano Tiziani	2
17	Novel estrogen receptor beta agonist S-equol decreases tumor proliferation in patients with triple negative breast cancer (TNBC). 2020 ·Journal of Clinical Oncology ·Kate Lathrop, Virginia Kaklamani, Andrew Brenner, Rong Li, Alia Nazarullah, (unknown), (unknown), Jonathan Gelfond, (unknown), Richard Elledge	10
18	Tyrosine phosphorylation regulates ERβ ubiquitination, protein turnover, and inhibition of breast cancer 2016 ·Oncotarget ·Bin Yuan, Long Cheng, Kshama Gupta, Huai-Chin Chiang, Harshita B. Gupta, Gangadhara R. Sareddy, Degeng Wang, Kate Lathrop, Richard Elledge, Pei Wang, Stanton F. McHardy, Ratna K. Vadlamudi, Tyler J. Curiel, Yanfen Hu, Qinong Ye, Rong Li	19
19	Breast Cancer Treatment Delays in a Majority Minority Community: Is There a Difference? 2015 ·Journal of Oncology Practice ·Helen Parsons, Kate Lathrop, Susanne Schmidt, (unknown), (unknown), (unknown), Anand B. Karnad	6
20	Correlation between Oncotype DX score with histologic grade, tumor size and Ki67 in patients with early stage breast cancer: A single academic institution experience. 2015 ·Journal of Clinical Oncology ·Kate Lathrop, (unknown), Jonathan Gelfond, (unknown), (unknown), (unknown)	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact